Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

1-3 Month T-Bill Barclays Capital SPDR (BIL)

1-3 Month T-Bill Barclays Capital SPDR (BIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Warren Buffett Is Buying Treasury Bills Hand Over Fist. Is Now a Good Time to Buy?

This key Berkshire Hathaway holding offers an impressive yield amid tough stock market conditions.

BRK.AX : 0.012 (unch)
BRK.A : 652,997.19 (+2.11%)
BRK.B : 434.42 (+2.35%)
ORCL : 143.07 (-1.17%)
BRK-A : N/A (N/A)
BRK-B : N/A (N/A)
BIL : 91.60 (+0.02%)
BILS : 99.21 (+0.03%)
Can You Actually Retire a Millionaire With ETFs Alone?

As long as you're paying attention to when you need the money and start your planning early, it's quite possible to reach that goal.

SPY : 561.53 (+0.28%)
BSCN : 21.19 (-0.35%)
BSCO : 21.11 (unch)
BSCP : 20.56 (+0.05%)
BSCQ : 19.34 (unch)
BSCR : 19.43 (unch)
BIL : 91.60 (+0.02%)
ALERT: 2 ETFs to Hold in a U.S. Recession

Experts and analysts have warned of a looming recession as North American economies have wrestled with ...

BIL : 91.60 (+0.02%)
VDC : 204.08 (-0.59%)

Barchart Exclusives

1 Big Pharma Dividend Stock to Snag While It's Still Cheap
Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar